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Mammalian cells are equipped with so-called “restriction factors” that suppress virus replication 
and help to prevent virus transmission from one species to another. This Essay discusses the host 
restriction factor tetherin, which blocks the release of enveloped viruses like HIV-1, and the factors 
evolved by primate lentiviruses, such as Vpu and Nef, that antagonize tetherin’s action.Constant exposure to a wide variety of 
viral pathogens during human evolu-
tion has shaped our genetic material. 
Indeed, ?8% of our genome consists of 
the defective remnants of once-infec-
tious retroviruses. Recent data suggest 
that these continuous encounters with 
viral pathogens over millions of years 
have driven the evolution of antiviral 
host factors that may help to control 
virus spread and to prevent cross-
species transmission of viral patho-
gens. These so called “host restriction” 
factors are components of the innate 
immune response and interfere with 
different stages of the virus life cycle. 
They can be constitutively expressed or 
may be induced by interferon-α (IFN-α) 
during induction of the innate immune 
response by viral infection. There are 
three main classes of restriction fac-
tors that are effective against retrovi-
ruses: cytidine deaminases such as 
APOBEC3G (apolipoprotein B mRNA-
editing enzyme 3G), which induces 
lethal hypermutations in the retroviral 
genome; TRIM5α (tripartite motif pro-
tein 5α) proteins, which restrict the 
incoming retroviral capsid; and teth-
erin (also known as BST-2, CD317, or 
HM1.24), which impedes the release of 
newly formed virions of human immuno-
deficiency virus (HIV-1) and other envel-
oped viruses from the host cell surface 
(Malim and Emerman, 2008; Neil and 
Bieniasz, 2009). Usually, these factors 
efficiently restrict retroviral infection, 
but, as a counterstrike, viruses have 
evolved specific antagonists to oppose 
their action. For example, in HIV-1 and 
the closely related simian immunodefi-
ciency viruses (SIVs), the viral proteins 
Vpu or Nef interfere with the action of 
tetherin. Here, we summarize our cur-392 Cell 141, April 30, 2010 ©2010 Elsevier rent knowledge of tetherin and specu-
late on its possible role in the patho-
genesis and spread of HIV-1.
Tetherin: Structure and Function
The host restriction factor tetherin was 
discovered a few years ago by the 
groups of Bieniasz and Guatelli (Neil et 
al., 2008; Van Damme et al., 2008). It has 
long been known that the Vpu protein 
of HIV-1 is required for efficient release 
of viral particles from certain cell types 
(e.g., HeLa cells) but not from others 
(e.g., COS-7 cells) (Strebel et al., 1989; 
Göttlinger et al., 1993). Heterokaryons 
formed between HeLa cells and COS-7 
cells showed the characteristics of 
HeLa cells, suggesting the expres-
sion of a dominant restrictive factor 
that is antagonized by Vpu (Varthakavi 
et al., 2003). This factor is induced by 
type I interferons and efficiently teth-
ers virions to the host cell surface (Neil 
et al., 2007). Bieniasz and colleagues 
identified this factor as BST-2/tetherin 
by using microarray analyses to com-
pare the expression of genes encod-
ing membrane-associated proteins 
that were constitutively expressed in 
cells where Vpu was required for effi-
cient virion release versus cells where 
Vpu was only required after IFN-α 
treatment (Neil et al., 2008). Indepen-
dently, Van Damme et al. (2008) identi-
fied BST-2/tetherin by extending work 
showing that BST-2 is downmodulated 
by the Vpu protein of HIV-1 and by the 
K5 protein of Kaposi’s sarcoma asso-
ciated herpes virus (KSHV) (Bartee et 
al., 2006).
Tetherin is a 30–36 kDa type II single-
pass transmembrane protein. It com-
prises a cytoplasmic N-terminal region, 
followed by a transmembrane domain, Inc.a coiled-coil extracellular domain, and 
a C-terminal glycosylphosphatidylinos-
itol (GPI) anchor (Kupzig et al., 2003). 
The ectodomain of tetherin contains 
two N-linked glycosylation sites and 
three cysteine residues that mediate 
homodimerization. The extracellular 
core region of tetherin forms a paral-
lel disulfide-linked coiled-coil domain, 
and the entire extracellular domain may 
adopt an extended 170 Å long rod-like 
structure (Hinz et al., 2010). Interest-
ingly, the coiled-coil domain of tetherin 
contains several conserved destabiliz-
ing amino acid residues, possibly pro-
viding sufficient conformational flex-
ibility to enable the GPI anchor to be 
inserted into the budding virion enve-
lope and the transmembrane domain 
to be embedded in the host cell plasma 
membrane. The topology of tetherin 
with both a GPI anchor and a trans-
membrane domain is highly unusual 
and is only shared by an isoform of the 
prion protein (Moore et al., 1999). Nota-
bly, the GPI anchor enables tetherin to 
be targeted to cholesterol-rich lipid 
rafts in the plasma membrane (Kupzig 
et al., 2003), the preferential site for HIV 
virion budding.
Tetherin is usually only expressed 
efficiently in plasmacytoid dendritic 
cells, some cancer cells, terminally dif-
ferentiated B cells, and bone marrow 
stromal cells (Blasius et al., 2006). How-
ever, its expression is strongly induced 
by type I IFNs (Neil et al., 2007). Induc-
tion of IFN expression by HIV-1 in vitro 
involves binding of HIV-1 virions to the 
CD4 receptor on plasmacytoid den-
dritic cells (the major producers of IFN), 
endocytosis of the virions, and trigger-
ing of Toll-like receptors (TLRs) 7 and 
9 by viral nucleic acids in endosomes 
Figure 1. Tetherin and Antiviral Activity
HIV-1 infection induces production of interferons (IFNs) by plasmacytoid dendritic cells in the host. HIV-1 first binds to the CD4 receptor expressed by these 
dendritic cells, is endocytosed, and then the viral RNA/DNA binds and activates Toll-like receptors (TLRs) 7 and 9 in endosomes resulting in the expression of 
IFN genes. IFN-α and IFN-β induce expression of tetherin via the JAK/STAT signaling pathway. Tetherin cycles between the trans-Golgi network and the cell 
surface; it binds to ILT7 to prevent overproduction of proinflammatory cytokines by plasmacytoid dendritic cells through a negative feedback loop. Tetherin 
blocks release of budding HIV-1 virions by inserting one or both of its membrane anchors into the envelope of the virions, thus anchoring them to the host cell 
surface. This results in the endocytosis and (most likely) lysosomal degradation of the virus particles. In the case of HIV-1, the Vpu protein of the virus antago-
nizes the action of tetherin (not shown). ISRE, interferon-stimulated response element.(Figure 1) (Beignon et al., 2005; Haupt 
et al., 2008; Mandl et al., 2008). Type I 
IFNs induce expression of several hun-
dred different genes and activate natu-
ral killer cells, myeloid dendritic cells, 
T and B cells, and macrophages. Teth-
erin expression is induced by the JAK/
STAT signaling pathway after binding 
of IFN-α and IFN-β to their receptors 
(Figure 1). Notably, the tetherin gene 
promoter contains various response 
elements, suggesting that other inflam-
matory cytokines, such as IL-6 and 
TNFα, may also induce its expression. 
Tetherin moves cotranslationally into 
the endoplasmic reticulum (ER) and is 
transported first to the compartments 
of the Golgi apparatus via COPII-coated 
vesicles and finally to the plasma mem-
brane (Figure 1). It binds to AP2 adap-
tor complexes via conserved tyrosines 
in its cytoplasmic tail, is internalized 
via clathrin-mediated endocytosis, and 
cycles between the cell surface and the trans-Golgi network (Rollason et al., 
2007). To prevent immune hyperactiva-
tion, tetherin binds to immunoglobulin-
like transcript 7 (ILT7) on plasmacytoid 
dendritic cells and inhibits the expres-
sion of type I IFNs and other proinflam-
matory cytokines in a negative feed-
back loop (Cao et al., 2009).
Tetherin’s Antiviral Action
The inefficient release of HIV-1 virions in 
the absence of the viral factor Vpu as a 
result of the action of tetherin is asso-
ciated with the accumulation of virions 
at the plasma membrane and within 
intracellular clathrin-coated endosomal 
structures (Neil et al., 2006). The virions 
trapped at the cell surface are infectious 
and can be released by physical shearing 
or subtilisin treatment (Neil et al., 2006; 
Kaletsky et al., 2009). Importantly, the 
inhibitory mechanism is relatively non-
specific, as tetherin restricts the release 
of different retroviruses, including alpha-, Cell 1beta-, delta-, spuma-, and lentiviruses, 
arenaviruses (Lassa), filoviruses (Mar-
burg, Ebola), and herpesviruses (KSHV) 
(Göttlinger et al., 1993; Jouvenet et al., 
2009; Sakuma et al., 2009; Mansouri et 
al., 2009; Kaletsky et al., 2009; Neil et al., 
2008).
The fact that tetherin contains two 
membrane anchors suggests that 
it may directly tether newly form-
ing virions to host cells. Bieniasz and 
colleagues have shown that it is the 
unusual structure of tetherin and not 
the primary sequence that determines 
its antiviral activity (Perez-Caballero et 
al., 2009). These authors generated an 
artificial protein with a different amino 
acid sequence but comparable topol-
ogy and found that it efficiently inhibits 
virus release. Thus, tetherin may not 
need a cofactor but rather tethers viri-
ons directly to the plasma membrane 
and to one another (Figure 1). This sim-
ple mechanism is in agreement with the 41, April 30, 2010 ©2010 Elsevier Inc. 393
finding that removal of either the cyto-
plasmic tail or the GPI anchor abolishes 
the antiviral activity of tetherin (Neil et 
al., 2008). It is not yet clear whether it 
is the transmembrane domain or the 
GPI anchor of tetherin that is inserted 
into the viral envelope. However, the 
observation that tetherin can also 
tether virions to one another implies 
that both domains can be incorpo-
rated into viral membranes. But many 
questions remain including the role of 
dimerization in the tethering mecha-
nism. Dimerization seems to be critical 
for tetherin’s inhibition of the release 
of HIV-1 virions (Perez-Caballero et 
al., 2009) but not of filovirus particles 
(Sakuma et al., 2009). Furthermore, it is 
still not clear whether the association 
of tetherin with lipid rafts and its inter-
action with the actin cytoskeleton help 
to recruit this restriction factor to sites 
of virus budding (Kupzig et al., 2003; 
Rollason et al., 2009). Recent data sug-
gest that the RING-type E3 ubiquitin 
ligase breast cancer-associated gene 
2 (BCA2; also called Rabring7, ZNF364, 
or RNF115) accelerates the internaliza-
tion and degradation of tethered HIV-1 
virions and may thus be a cofactor for 
tetherin (Miyakawa et al., 2009). Also, 
it is not known whether endocytosed 
tethered virions are generally degraded 
in lysosomes or whether they may 
remain intact and cycle back to the cell 
surface.
Vpu Antagonizes Tetherin
Tetherin was discovered because it 
is antagonized by the HIV-1 protein 
Vpu. This accessory viral factor is a 
16 kDa type 1 transmembrane protein 
that seems to interact directly with 
the transmembrane domain of teth-
erin. This interaction is highly specific 
as single point mutations in tetherin’s 
transmembrane domain render it resis-
tant to Vpu (McNatt et al., 2009; Gupta 
et al., 2009). Vpu leads to moderately 
reduced levels of tetherin at the host 
cell surface and a modest decrease in 
total cellular tetherin (Van Damme et 
al., 2008; Mitchell et al., 2009; Doug-
las et al., 2009). This may be achieved 
by targeting tetherin to the trans-Golgi 
network or to early endosomes for pro-
teasomal or lysosomal degradation 
by a β-TrCP-dependent mechanism 394 Cell 141, April 30, 2010 ©2010 Elsevier (Douglas et al., 2009; Goffinet et al., 
2009; Gupta et al., 2009; Mangeat et 
al., 2009) (Table S1 available online). 
However, mutations in the TrCP-bind-
ing motif in Vpu do not entirely dis-
rupt its ability to antagonize tetherin 
and promote virion release (Schubert 
and Strebel, 1994; Van Damme et al., 
2008), and downmodulation of teth-
erin may not always be required for 
Vpu to promote virion release (Miyagi 
et al., 2009; Neil et al., 2008; Dubé et 
al., 2010). Thus, the exact mechanisms 
of tetherin downmodulation from the 
cell surface and intracellular degrada-
tion or sequestration, as well as the 
relative contribution of these effects to 
Vpu-dependent enhancement of virion 
release, remain to be determined.
Most primate lentiviruses do not con-
tain a vpu gene. Indeed, some primate 
lentiviruses (e.g., SIVsmm, SIVmac, 
SIVsyk, and SIVagm from sooty mang-
abeys, macaques, Syke’s monkeys, and 
African green monkeys, respectively) use 
their Nef proteins to antagonize tetherin 
(Jia et al., 2009; Sauter et al., 2009; Zhang 
et al., 2009). Surprisingly, SIVcpz from 
chimpanzees and SIVgor from gorillas, 
which contain Vpu and are the ancestors 
of HIV-1, also use Nef to block tetherin. 
Nef is a myristoylated protein that is criti-
cal for efficient viral replication in vivo 
and manipulates cellular trafficking, sig-
nal transduction, and gene expression in 
host cells. How Nef antagonizes tetherin 
is unclear, but Nef is known to act as 
an adaptor protein, interacting with the 
cytoplasmic domains of CD4, CD28, and 
class I MHC molecules and downmodu-
lating their expression by recruiting them 
to the endocytic machinery or re-routing 
them to lysosomes for degradation. Nef 
also targets the cytoplasmic tail of teth-
erin and reduces its expression at the 
host cell surface (Jia et al., 2009; Zhang 
et al., 2009). Certain mutations in Nef that 
disrupt its effect on tetherin also abolish 
CD4 downregulation implicating a similar 
mechanism in both events, such as AP2-
dependent endocytosis and lysosomal 
degradation.
In contrast to its direct simian precur-
sor (SIVsmm from naturally infected sooty 
mangabeys; Gao et al., 1992), HIV-2 uses 
its envelope glycoprotein Env (and not 
Nef) to antagonize tetherin by sequester-
ing it away from sites of virus assembly Inc.(Le Tortorec and Neil, 2009). The Env 
glycoprotein of HIV-2 seems to interact 
directly with the ectodomain of tetherin, 
and its ability to promote virus release 
requires an intact Gyxxθ motif that binds 
to AP2 and targets it for clathrin-medi-
ated endocytosis. Interestingly, SIVtan 
from Tantalus monkeys uses both Env 
and Nef to antagonize tetherin (Gupta 
et al., 2009; Zhang et al., 2009). It is not 
known whether simple retroviruses that 
do not encode Vpu or Nef can use Env 
to counteract tetherin or whether they do 
not require a tetherin antagonist because 
they do not induce an inflammatory type 
I IFN response. Herpesviruses and filovi-
ruses encode tetherin antagonists; KSHV 
uses K5/MIR2, a viral member of the 
membrane-associated RING-CH ubiq-
uitin ligase family, to ubiquitinate teth-
erin at lysines K18 and K28 and target it 
for degradation (Mansouri et al., 2009). 
Tetherin-mediated restriction of filovirus 
budding is antagonized by the Ebola virus 
glycoprotein (Kaletsky et al., 2009), but 
this does not seem to involve a reduction 
in tetherin expression. Like the HIV-2 and 
SIVtan Env glycoproteins, the Ebola virus 
glycoprotein may sequester tetherin away 
from the site of virus budding (Table S1).
Tetherin and Primate Lentivirus 
Evolution
Genes encoding host restriction factors 
show strong evidence for positive selec-
tion and have evolved rapidly. This diver-
sifying selection is most likely driven by 
the need to combat new emerging patho-
gens or new viral antagonist proteins. As a 
consequence, these antiviral factors show 
a high degree of sequence divergence 
and may constitute barriers to zoonotic 
viral transmission from animal reservoirs 
because the viral antagonists often act in 
a species-specific manner. For example, 
the HIV-1 Vpu protein antagonizes human 
but not monkey tetherin (Gupta et al., 
2009; McNatt et al., 2009), whereas the 
Vpu proteins of SIVgsn, SIVmon, and SIV-
mus show the opposite phenotype and 
counteract monkey but not human or ape 
tetherins (Sauter et al., 2009). However, 
primate lentiviruses are well known for 
their ability to cross species barriers and 
to adapt rapidly to a new host environment 
(Figure 2A). SIVcpz most likely arose from 
a recombination event between ancestors 
of SIVs that presently infect Red-capped 
mangabeys and Cercopithecus monkeys 
(Bailes et al., 2003). Subsequently, SIVcpz 
was transmitted from chimpanzees to 
gorillas, giving rise to SIVgor, and to 
humans, giving rise to pandemic group M, 
rare group N, and (possibly) nonpandemic 
group O strains of HIV-1 (Van Heuverswyn 
and Peeters, 2007). A new virus (desig-
nated HIV-1 group P) that is closely related 
to SIVgor and most likely was transmitted 
from gorillas to humans has been recently 
identified (Plantier et al., 2009).
How do these primate lentiviruses 
antagonize tetherin? The ancestor of 
SIVrcm most likely used Nef to antagonize 
tetherin (because SIVrcm does not have 
Vpu), and the ancestor of the SIVgsn/mus/
mon lineage most probably used Vpu 
(because its descendants do) (Sauter et 
al., 2009). Phylogenetic analyses suggest 
that SIVcpz received the vpu gene from 
the predecessor of the SIVgsn/mus/mon 
lineage and nef from the SIVrcm lineage 
(Schindler et al., 2006). The transmem-
brane domain of chimpanzee and mon-
key tetherin that is targeted by Vpu differs 
by seven amino acids and a small dele-
tion (Figure 2B). The cytoplasmic domain 
of tetherin that seems to interact with Nef 
is less divergent, which may explain why 
Nef and not Vpu evolved to become an 
effective tetherin antagonist in SIVcpz-
infected chimpanzees.
After zoonotic transmission of SIVcpz 
from chimpanzees to gorillas the Nef of 
SIVgor was able to adapt rapidly to antag-
onize gorilla tetherin because the cyto-
plasmic domain of gorilla and chimpanzee 
tetherin differs by only two amino acids. 
However, human tetherin is resistant to 
Nef because there is a five amino acid 
deletion in its cytoplasmic domain (Figure 
2B), which may have evolved to escape 
the protein antagonists of ancient lentivi-
ruses (Zhang et al., 2009). This deletion 
poses a significant barrier for viral trans-
mission from chimpanzees to humans 
Figure 2. Tetherin and Lentivirus Evolution
Viral antagonists of tetherin in the primate lentiviral 
lineages from which HIV-1 arose.
(A) The simian immunodeficiency virus (SIV) of 
chimpanzees (SIVcpz) is thought to be a recom-
binant between the predecessor of SIVrcm found 
in Red-capped mangabeys and the common 
vpu-containing ancestor of SIVgsn, SIVmus, and 
SIVmon that currently infect Greater spot-nosed, 
Mustached, and Mona monkeys (Bailes et al., 
2003). Chimpanzees prey on these monkeys ex-
plaining why they became coinfected with both 
simian viruses. SIVcpz was later transmitted to hu-
mans and gorillas, evolving into HIV-1 and SIVgor, 
respectively. It is not known whether HIV-1 group 
O strains originated from chimpanzees or gorillas 
(dashed line). The host restriction factor tetherin is 
antagonized by the viral protein Vpu (red) or Nef 
(blue) depending on the SIV or HIV strain.
(B) Alignment of the amino acid sequences of the 
N-terminal region of tetherin from Greater spot-
nosed monkeys (GSN), Mustached monkeys 
(MUS), Mona monkeys (MON), sooty mangabeys 
(SMM), chimpanzees (CPZ), gorillas (GOR), and 
humans (HU). Shown are the cytoplasmic and 
transmembrane domains targeted by Nef and Vpu. 
Amino acid differences and deletions (framed) that 
may pose barriers to cross-species virus trans-
mission are highlighted by boxes. (The tetherin se-
quence of the sooty mangabey is shown as that of 
the Red-capped mangabey is not available.)
(C) Switches between Vpu-, Nef-, and Env-de-
pendent antagonism of tetherin in SIV strains that 
preceded the emergence of HIV-1 and HIV-2. Vpu 
interacts with tetherin via its transmembrane do-
main. Nef interacts with the cytoplasmic domain 
of tetherin, which contains a deletion in the hu-
man protein but not in the tetherins of nonhuman 
primates. The interaction site for HIV-2 Env and 
human tetherin is unknown but may be located 
in tetherin’s ectodomain. Photos courtesy of M.L. 
Wilson, Cecile Neel, and Martine Peeters.Cell 141, April 30, 2010 ©2010 Elsevier Inc. 395
and most likely forced HIV-1 to switch 
from Nef to Vpu to counteract tetherin in 
its new human host (Figure 2C). Notably, 
only pandemic HIV-1 M strains mastered 
this hurdle perfectly by regaining efficient 
Vpu-mediated antitetherin activity. In con-
trast, the Vpu proteins of HIV-1 O and P 
strains are poor tetherin antagonists, and 
those of the rare HIV-1 group N strains 
gained some antitetherin activity but lost 
the ability to degrade CD4 (Sauter et al., 
2009; D.S., A.S., and F.K., unpublished 
data). The sequence variations underlying 
these differences in Vpu function among 
the different HIV-1 strains remain to be 
elucidated. The resistance of human teth-
erin to Nef may also explain why HIV-2, 
which originated from SIVsmm, switched 
from Nef to the Env glycoprotein in order 
to suppress tetherin’s action (Le Tortorec 
and Neil, 2009) (Figure 2C).
Tetherin and HIV-1 Pathogenesis
The fact that viruses have developed 
highly specific tools to antagonize 
tetherin clearly suggests that this host 
restriction factor is a significant inhibi-
tor of virus replication in vivo. However, 
the importance of the type I IFN immune 
response and of tetherin antagonists for 
control of HIV-1 replication in vivo and for 
HIV-1 pathogenesis remains to be fully 
defined. Chimeric SIVmac constructs 
expressing the HIV-1 nef gene (SHIV) 
can cause fatal disease in macaques 
(Alexander et al., 1999; Kirchhoff et 
al., 1999), although the Nef of HIV-1 is 
unable to antagonize tetherin. HIV-1 O 
strains show reduced replicative fitness 
in cell culture and spread less efficiently 
in the human population than the HIV-1 
M strain but can cause AIDS (Mauclère 
et al., 1997) even though their Vpu and 
Nef proteins are poor tetherin antago-
nists (Sauter et al., 2009). It remains 
to be clarified whether the HIV-1 Nef 
protein acquired antitetherin activity in 
SHIV-infected macaques and whether 
HIV-1 O strains may use another protein 
to antagonize tetherin. Nonetheless, 
these findings raise the possibility that 
effective tetherin antagonism may not 
be obligatory for efficient viral replica-
tion and disease progression in vivo. 
One possible reason for the presumably 
limited relevance of tetherin to HIV-1 
pathogenesis and the development 
of AIDS is that tetherin and other host 396 Cell 141, April 30, 2010 ©2010 Elsevier restriction factors may inhibit the cell-
to-cell spread of virus (a potent means 
of virus replication in vivo) less efficiently 
than the spread of cell-free virions (Ven-
drame et al., 2009). Vpu-defective HIV-1 
shows enhanced cell-to-cell trans-
mission (Gummuluru et al., 2000), and 
tetherin has been detected in biofilm-
like extracellular viral assemblies that 
mediate cell-to-cell transmission of the 
lentivirus HTLV-1 (Pais-Correia et al., 
2010). However, HIV-1 mutants lacking 
Vpu replicate less effectively than wild-
type virus in ex vivo-infected human 
lymphoid tissues (Schindler et al., 2010). 
Thus, further studies on the effect of 
tetherin on the cell-to-cell spread of 
viruses are warranted. The finding that 
only Vpu proteins of pandemic HIV-1 M 
strains are effective against both teth-
erin and CD4 suggests a role for these 
Vpu functions in sexual transmission of 
HIV-1 within the human population, pos-
sibly by affecting the shedding of infec-
tious virions into genital fluids. Further 
studies comparing the rates of virus 
transmission and disease progression 
in infections caused by HIV-1 M and O 
(and as far as possible N and P) strains 
are needed to clarify the importance of 
tetherin antagonism and Vpu-mediated 
CD4 degradation in vivo.
Tetherin and Antiretroviral Therapy
Increased expression of tetherin at the 
host cell surface can suppress the release 
and replication of wild-type HIV-1 strains 
in cell culture (Neil et al., 2007; Sauter et 
al., 2009). IFN-α treatment and hence 
the induction of tetherin and other host 
restriction factors is known to reduce 
HIV-1 viremia in infected patients; how-
ever, these effects are often transient and 
accompanied by adverse reactions, such 
as flu-like symptoms and depression. 
A major problem is that IFN-α has both 
beneficial effects, because it inhibits virus 
replication, and harmful consequences, 
as it contributes to immune activation that 
helps to drive progression to AIDS (Her-
beuval and Shearer, 2007). Notably, dif-
ferences in the induction of the type I IFN 
immune response may distinguish patho-
genic and nonpathogenic primate lentivi-
ral infections. During the acute phase of 
infection, a strong type I IFN response is 
activated by both pathogenic and non-
pathogenic lentiviruses, but this response Inc.is rapidly controlled and returns to basal 
levels only in nonpathogenic virus infec-
tions (Bosinger et al., 2009; Jacquelin et 
al., 2009). Thus, effective downmodulation 
of the type I IFN response may help the 
natural nonhuman primate hosts of SIVs 
to prevent the harmful chronic immune 
activation that drives progression to AIDS 
in HIV-1-infected individuals.
Another study on gender differences 
in HIV-1 infection suggests that the 
favorable and adverse effects of IFN-α 
may compensate each other. Plas-
macytoid dendritic cells derived from 
women produce more IFN-α in response 
to HIV-1 infection, and women tend to 
have lower viral loads than men (Meier 
et al., 2009). On average, women prog-
ress to AIDS about as fast as men do. 
At the same viral loads, however, women 
show higher levels of immune activation 
and faster disease progression. Thus, it 
is questionable whether long-term clini-
cal benefits can be achieved with IFN-α 
treatment. It may be possible to induce 
tetherin expression in a more specific 
manner (i.e., without causing systemic 
inflammation) or only at specific sites. 
Another strategy is to develop specific 
inhibitors of the viral antagonists of teth-
erin. But even complete loss of Vpu does 
not entirely impair the ability of HIV-1 to 
replicate in peripheral blood mononu-
clear cell cultures or in ex vivo-infected 
human lymphoid tissues (Neil et al., 2007; 
Schindler et al., 2010), suggesting that 
this strategy may not be very efficient. 
Nonetheless, further studies that induce 
tetherin expression or block its viral 
antagonists are required, particularly as 
tetherin targets the plasma membrane of 
the host cell that becomes the viral enve-
lope. Tetherin is effective against a large 
number of viral pathogens, and it will be 
difficult for HIV-1 and other viruses to 
develop resistance to this host restric-
tion factor.
Perspectives
We are only beginning to understand 
the complex interactions between viral 
pathogens and their hosts. For example, 
additional host restriction factors remain 
to be discovered, and the functions of 
many genes induced by IFN-α are only 
starting to be elucidated. One caveat 
is that most of the data about tetherin 
and the viral proteins that antagonize 
it has been obtained using transfected 
cells that are not usually susceptible to 
HIV or SIV infection. To elucidate the 
role of tetherin and its antagonists in 
viral release, replication, pathogenesis, 
and transmission, it will be important 
to study replication-competent viruses 
in primary cells, ex vivo explant tissues, 
and animal models. Such studies should 
also reveal whether Vpu is a more effec-
tive tetherin antagonist than Nef, which 
may help to clarify why HIV-1 evolved to 
cause greater chronic immune activation 
than natural SIV infections (Kirchhoff, 
2009). Furthermore, such analyses are 
needed to accurately assess whether 
the induction of host restriction factors 
or inhibition of their viral antagonists 
represent useful therapeutic strategies. 
The discovery of tetherin and other host 
restriction factors may also lead to the 
development of improved animal mod-
els. Finally, the recent generation of an 
artificial tetherin (Perez-Caballero et al., 
2009) suggests that it may be possible 
to develop improved restriction factors 
with broad-based antiviral activity that 
are resistant to the action of viral antag-
onists. Further research will not only 
provide exciting new insights into the 
struggle between viruses and their hosts 
but may also lead to new therapeutic 
interventions for treating HIV and other 
viral infections.
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